Outras Publicações

2021

Autoimmune hepatitis in patients aged 70 years or older: Disease characteristics, treatment response and outcome
Dalekos GN, Azariadis K, Lygoura V, Arvaniti P, Gampeta S, Gatselis NK.
Liver Int. 2021;41(7):1592-1599.
doi:10.1111/LIV.14900
link

Comparison of fondaparinux and low molecular weight heparin in the treatment of portal vein thrombosis in cirrhosis
Senzolo M, Piano S, Shalaby S, et al.
Am J Med. 2021;0(0).
doi:10.1016/J.AMJMED.2021.05.013
link

Risks and Benefits of Discontinuation of Nucleos(t)ide Analogue Treatment: A Treatment Concept for Patients With HBeAg‐Negative Chronic Hepatitis B
Bömmel F, Berg T.
Hepatol Commun. 2021;0(0):1-17.
doi:10.1002/hep4.1708
DESCARREGUE AQUI O PDF

Early diarrhoea under sorafenib as a marker to consider the early migration to second ‐ line drugs
González ÁD, Sapena V, Zamparelli MS, et al.
2021;(January).
doi:10.1002/ueg2.12111
DESCARREGUE AQUI O PDF

Estrogens in Polycystic Liver Disease: A Target for Future Therapies?
Aapkes SE, Bernts LHP, Barten TRM, den Berg M, Gansevoort RT, Drenth JPH.
2021.
doi:10.1111/liv.14986
DESCARREGUE AQUI O PDF

The systemic inflammation hypothesis: Towards a new paradigm of acute decompensation and multiorgan failure in cirrhosis
Arroyo V, Angeli P, Moreau R, et al.
J Hepatol. 2021;74(3):670-685.
doi:10.1016/j.jhep.2020.11.048
DESCARREGUE AQUI O PDF

Clinical management of patients with drug‐induced liver injury (DILI)
Björnsson ES.
United Eur Gastroenterol J. 2021;(March):1-6.
doi:10.1002/ueg2.12113
DESCARREGUE AQUI O PDF

End-stage liver disease: Management of hepatorenal syndrome
Mauro E, Garcia-Olveira L, Gadano A.
Liver Int. 2021;41(S1):119-127.
doi:10.1111/liv.14866
DESCARREGUE AQUI O PDF

Micronutrient deficiencies in patients with decompensated liver cirrhosis
Llibre-Nieto G, Lira A, Vergara M, et al.
Nutrients. 2021;13(4):1-14.
doi:10.3390/nu13041249
DESCARREGUE AQUI O PDF

EASL-CLIF criteria perform better than NACSELD to diagnose and prognosticate ACLF
Li F, Thuluvath PJ.
J Hepatol. Published online 2021.
doi:10.1016/j.jhep.2021.05.033
link

Pharmacotherapy for Weight Loss in Cirrhosis and Liver Transplantation: Translating the Data and Underused Potential
Brown SA, Izzy M, Watt KD.
Hepatology. 2021;73(5):2051-2062.
doi:10.1002/hep.31595
link

Identification of optimal therapeutic window for steroid use in severe alcohol-associated hepatitis: a worldwide study
Arab JP, Díaz LA, Baeza N, et al.
European Association for the Study of the Liver; 2021.
doi:10.1016/j.jhep.2021.06.019
link

Direct Measurement of ATP7B Peptides Is Highly Effective in the Diagnosis of Wilson Disease
Collins CJ, Yi F, Dayuha R, et al.
Gastroenterology. 2021;160(7):2367-2382.e1.
doi:10.1053/j.gastro.2021.02.052
descarregue aqui o pdf

Weight-loss-independent benefits of exercise on liver steatosis and stiffness in Japanese men with NAFLD
Oh S, Tsujimoto T, Kim B, et al.
JHEP Reports. 2021;3(3):100253.
doi:10.1016/j.jhepr.2021.100253
descarregue aqui o pdf

2020

A randomised, double-blind, placebo-controlled, multi-centre, dose-range, proof-of-concept, 24-week treatment study of lanifibranor in adult subjects with non-alcoholic steatohepatitis: Design of the NATIVE study. Contemp Clin Trials
Sven M. F, Pierre B, Manal F. A, et al.
2020;98(August):106170.
doi:10.1016/j.cct.2020.106170
descarregue aqui o pdf

Long-term outcomes in patients with decompensated alcohol-related liver disease, steatohepatitis and Maddrey’s discriminant function <32
Degré D, Stauber RE, Englebert G, et al.
J Hepatol. 2020;72(4):636-642.
doi:10.1016/j.jhep.2019.12.023
descarregue aqui o pdf

Development of an RNAi therapeutic for alpha-1-antitrypsin liver disease
Wooddell CI, Blomenkamp K, Peterson RM, et al.
JCI Insight. 2020;5(12):1-19.
doi:10.1172/jci.insight.135348
descarregue aqui o pdf

APEF - ASSOCIAÇÃO PORTUGUESA PARA O ESTUDO DO FÍGADO
Rua Abranches Ferrão, nº 10 - 14º
1600-001 Lisboa Tel: 217995536 
Fax: 217995538
geral@apef.com.pt

Horário de funcionamento:
9.00 - 13.00, 14.00 - 18.00

Secretariado

Luis Maco
Diretor-Geral
luis.maco@apef.com.pt
Andreia Neto
andreia.neto@apef.com.pt
Teresa Jorge
teresa.jorge@apef.com.pt
Cândida Rodrigues

Tornar-se sócio

É favor enviar ao Presidente da APEF, até 3 meses da data da Assembleia Geral, a proposta devidamente preenchida, assinada por dois sócios titulares da APEF e acompanhada das notas curriculares (resumo cv), para: Geral@apef.com.pt ou para

APEF - ASSOCIAÇÃO PORTUGUESA PARA O ESTUDO DO FÍGADO, Rua Abranches Ferrão

Nº10 - 14º 1600-001 Lisboa.

Ficha de Inscrição